VEGFA and neoplasm: Interestingly, we have observed that the same cancer model can experience an increase in hypoxia and vessel abnormality in response to an antiangiogenic (monoclonal antibody (mAb) against VEGF) and vascular normalization and tumor re-oxygenation in response to other antiangiogenic agents (nintedanib and dovitinib, multi-tyrosine-kinase inhibitors (TKIs) [34].